A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.
Autologous stem cell transplantation (ASCT) shows improved DFS and RFS compared to chemotherapy in AML patients achieving complete response. ASCT is associated with a 50% reduction in relapse risk ...
HOUSTON, May 7, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. (MBRX), (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates ...
A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia ...
LYT-200 plus HMA at 12 mg/kg delivered 45.5% ORR in 11 R/R HR-MDS patients, including 27.3% CRs, despite 100% prior HMA ...
Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year ...
Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year survival below 30% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results